Surgicure Technologies

WHO WE ARE - Surgicure Technologies is a medical technology platform company building the infrastructure for military-born medical breakthroughs to become the new standard of care. The team is made up of physicians, serial medical device entrepreneurs with multiple exits, and seasoned executives from large Enterprise such as Merck, Boston Scientific, Anika Therapeutics, Bay State Anesthesia, Roche Diagnostics, and more—backed by academic training from MIT and Harvard Medical School. WHAT WE DO - Leveraging deep subject matter expertise coupled with a unique network, we operate a five-spoke flywheel that identifies unmet clinical needs across military and civilian medicine, matches them to licensable military IP through a proprietary intelligence platform, validates devices in both channels simultaneously, and commercializes through live dual-channel infrastructure. Every device that passes through the platform inherits the same regulatory playbook, clinical network, manufacturing partner, distribution engine, and capital relationships—compressing the industry-standard 10–15 year license-to-commercialization timeline to under 2 years per device. - The HORSESHOE—Surgicure's platform proof-of-concept spun out of the U.S. Army—is a face-free airway security device that is exempt from FDA approval, live in use in the theatre of war, and generating initial hospital sales across the United States. WHY THIS MATTERS - Some of the most transformative technologies in modern history—from GPS to the EpiPen to modern trauma surgery—were born in military R&D. The U.S. military invests over $2 billion annually in medical R&D, yet up to 90% of battlefield-proven innovations never reach soldiers or civilians. There is no platform player that owns the end-to-end military-to-civilian medical device pipeline. Billions in Army, Navy, Air Force, and DARPA innovation sit unlicensed across airway, hemorrhage, TBI, burns, and surgical categories—invisible to the commercial market—while the civilian standard of care lags behind what medics already know works. This is not a product gap. It is a structural gap in how validated, life-saving innovations move from battlefield to bedside—and it spans every clinical category. The company that builds the repeatable infrastructure to close it—the licensing relationships, the regulatory playbook, the dual-use channel commercial engine—doesn't just build a medical device company. It builds the platform that the entire military-to-civilian MedTech pipeline runs through. This is what Surgicure is building. OUR UNFAIR ADVANTAGE - Exclusive Army license secured. Active relationships operational with Brooke Army Medical Center, Army Tech Transfer, and the U.S. Army Institute of Surgical Research. The only recurring military-civilian clinical consortium convening demand across six anchor cities being built. 2 co-development agreements with the military’s primary MedTech labs in process. A combat-validated device on active frontlines in Ukraine with the Chief Surgeon of the Armed Forces of Ukraine serving as an ongoing clinical intelligence partner—providing direct field feedback shaping our next generation of devices and an open channel for continued real-world validation at the point of greatest need. Federal law (PL 115-92) fast-tracks military-priority devices through FDA with breakthrough-style review—pathway extends to civilian use. The licensing relationships, regulatory playbook, and dual-channel commercial engine are designed from day one to scale across every device that follows. Built in alignment with the Tactical Combat Casualty Care guidelines and the mandates of leading patient safety, quality, and infection prevention organizations, each device we bring to market enters with a clear standard-of-care pathway already written around it—one that legacy devices, burdened by recall history and injury data, are disqualified from accessing. TRACTION TO DATE - FDA pathways cleared, full clinical validation complete: mechanical, biocompatibility human factors (Dartmouth), cadaver (Texas Tech), and human clinical testing (Mass General Brigham) complete. Zero adverse events. FDA Class I, 510(k)-exempt. ISO 13485-certified. - Live in theatre: combat-deployed on active frontlines and stabilization points in Ukraine. Federal and military procurement activated—registered across key DoD/DLA systems. - U.S.-based manufacturing live and selling—3 exclusive distributors (4th in diligence), ~60-70% U.S. market coverage secured through inbound demand, 124 active hospital opportunities, over $9M in evaluated pipeline, first POs in hand at full price. - Seed oversubscribed (January 2025). ~$2.4M raised to date. Techstars '24, MassChallenge '25, Tampa Bay Wave '26. OUR FAR-TERM STRATEGY - The HORSESHOE is the platform proof-of-concept. 6 additional military-born devices are in active pipeline evaluation—each inheriting our distributor network, regulatory precedent, military procurement access, and clinical credibility. Our pipeline gets cheaper and faster with every launch. - Build Surgicure into the defining medical device platform company—the one clinicians reach for when standard tools fail, the one the military trusts in the field, and the one acquirers will have to own to lead this space. - Underpinning all of it: a proprietary intelligence layer with standalone IP value—monitors DoD tech transfer, SBIR/STTR awards, and military medicine sources in real time—surfacing licensable IP 6-18 months before the market sees it, auto-screened and enriched against FDA pathway and commercial viability, competitive research, and evidence benchmarking before human time is invested. Airway is the proof point of a larger Wave 1 pipeline (airway, respiratory care, critical care transport, burn care, ICU patient safety), TAM: >$50B. Long-term platform ceiling: $600B+ global medical device market ($218B U.S.). OUR CURRENT ROUND - We are raising a $2M Pre-Growth Round focused on fulfilling existing contract demand and pipeline opportunities, manufacturing ramp, team expansion, and maximizing the downstream Series A. - Target Valuation: $15M pre-money - Runway Extension: 24 months - Previous Raises: $610K Pre-Seed; $1.785M Seed (oversubscribed; Launchpad Venture Group lead). Previous investors are doubling and tripling down.